转移性去势抵抗性前列腺癌中的免疫生物标志物
本研究对100例转移性去势抵抗性前列腺癌(mCRPC)活检组织进行全外显子测序、靶向二代测序、RNA测序、肿瘤突变负荷、T细胞炎症基因表达谱(TcellinfGEP)评分及PD-L1、ATM、PTEN、SOX2和神经内分泌特征的免疫组化检测,发现PD-L1蛋白表达、高TcellinfGEP评分和SOX2表达与更差的总生存(OS)相关。
要点
- PD-L1蛋白表达(CPS≥1)见于24例(33%)mCRPC活检,与更差OS相关(aHR 1.90)。
- 高TcellinfGEP评分(>-0.318)见于23例(26%)活检,与更差OS相关(aHR 1.86)。
- SOX2表达(>5%细胞)见于27例(27%)活检,与更差OS相关(aHR 2.09)。
核心结论
- PD-L1、TcellinfGEP评分和SOX2是mCRPC结局的预后指标。
- 若经验证,纳入生存终点的预测性生物标志物研究需考虑这些发现。
研究设计与样本
- 对100例患者的mCRPC活检组织进行全外显子测序、靶向二代测序、RNA测序、肿瘤突变负荷、TcellinfGEP评分(Nanostring)及PD-L1、ATM、PTEN、SOX2和神经内分泌特征的免疫组化检测。
主要发现
- PD-L1蛋白表达(联合阳性评分≥1)见于24例(33%)活检,SOX2蛋白表达(>5%细胞)见于27例(27%)活检,高TcellinfGEP评分(>-0.318)见于23例(26%)活检。
- PD-L1蛋白表达与TcellinfGEP评分呈正相关(phi 0.63 [0.45; 0.76])。
- PD-L1蛋白表达(aHR 1.90 [1.05; 3.45])、高TcellinfGEP评分(aHR 1.86 [1.04; 3.31])和SOX2表达(aHR 2.09 [1.20; 3.64])与更差OS相关。
关键数值与推荐
- PD-L1蛋白表达判定为联合阳性评分≥1。
- SOX2蛋白表达判定为>5%细胞。
- 高TcellinfGEP评分判定为>-0.318。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited. OBJECTIVE: To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: From 100 patients, mCRPC biopsies were assayed by whole exome sequencing, targeted next-generation sequencing, RNA sequencing, tumor mutational burden, T-cell-inflamed gene expression profile (TcellinfGEP) score (Nanostring), and immunohistochemistry for programmed cell death 1 ligand 1 (PD-L1), ataxia-telangiectasia mutated (ATM), phosphatase and tensin homolog (PTEN), SRY homology box 2 (SOX2), and the presence of neuroendocrine features. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The phi coefficient determined correlations between biomarkers of interest. OS was assessed using Kaplan-Meier curves and adjusted hazard ratios (aHRs) from Cox regression. RESULTS AND LIMITATIONS: PD-L1 and SOX2 protein expression was detected by immunohistochemistry (combined positive score ≥1 and >5% cells, respectively) in 24 (33%) and 27 (27%) mCRPC biopsies, respectively; 23 (26%) mCRPC biopsies had high TcellinfGEP scores (>-0.318). PD-L1 protein expression and TcellinfGEP scores were positively correlated (phi 0.63 [0.45; 0.76]). PD-L1 protein expression (aHR: 1.90 [1.05; 3.45]), high TcellinfGEP score (aHR: 1.86 [1.04; 3.31]), and SOX2 expression (aHR: 2.09 [1.20; 3.64]) were associated with worse OS. CONCLUSIONS: PD-L1, TcellinfGEP score, and SOX2 are prognostic of outcome from the mCRPC setting. If validated, predictive biomarker studies incorporating survival endpoints need to take these findings into consideration. PATIENT SUMMARY: This study presents an analysis of immune biomarkers in biopsies from patients with metastatic prostate cancer. We describe tumor alterations that predict prognosis that can impact future studies.
引用
- Fenor de la Maza MD, Chandran K, Rekowski J, et al. Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2022. PMID: 35491356. doi:10.1016/j.euo.2022.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。